In this article, we will take a look at the 25 best dividend aristocrat stocks.Dividend aristocrats are companies that have raised their dividends every year for at least 25 years. Investors tend to favor them because a long record of dividend growth creates confidence that payouts can keep rising over time.These companies are usually mature businesses with steady earnings. In many cases, management teams place dividends high on the capital structure, treating regular increases as a core responsibility. For ...

Core Insights - BD reported record revenue of $21.8 billion for fiscal 2025, reflecting a 7.7% growth on an adjusted foreign exchange-neutral basis and 2.9% organic growth, with management highlighting solid performance across key platforms in a dynamic market environment [1][5] - The company described fiscal 2025 as the culmination of its BD 2025 strategy and the beginning of a new growth phase, emphasizing the most prolific growth period in its 128-year history with over $5.4 billion in organic revenue added [1][7] - BD plans to close the combination of its Biosciences and Diagnostic Solutions business with Waters Corp. on February 9, allocating at least half of the expected $4 billion in cash proceeds to share repurchases and the remainder to debt repayment [4][13] Financial Performance - BD achieved a record adjusted operating margin of 25% and reported a 9.6% growth in adjusted diluted EPS, alongside returning $2.2 billion to shareholders, marking its 54th consecutive dividend increase [5][6][10] - The company launched over 125 new products and generated $1.3 billion through more than 20 tuck-in acquisitions while divesting non-strategic assets [8][10] Annual Meeting Outcomes - Shareholders approved all four proposals at the annual meeting, including the election of directors and the ratification of Ernst & Young as the independent auditor for fiscal 2026, with significant support for each proposal [3][15] - The advisory "Say on Pay" vote on executive compensation received approximately 91% support, and the amendment to the 2004 Equity Compensation Plan received 96% support [15] Strategic Initiatives - BD's management highlighted the BD Excellence operating system's contribution to profit and loss leverage, achieving record service levels and consumables quality while navigating macro challenges [6][10] - The company outlined an enhanced capital allocation framework focused on share repurchases, reliable and increasing dividends, and targeted high-growth market acquisitions [14]

作者：情报员 国家知识产权局信息显示，贝克顿·迪金森公司取得一项名为"防止提取粒子遗留的磁体组件"的专利， 授权公告号CN114585444B，申请日期为2020年12月。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 ...

Core Viewpoint - The collaboration between BD and Envetec has successfully demonstrated a feasible method for recycling polystyrene Petri dishes and other plastics used in healthcare, paving the way for sustainable practices in the industry [1][4]. Group 1: Recycling Feasibility - A joint feasibility study has shown that polystyrene, polyester (PET), polypropylene, and polyethylene can be recycled into high-quality manufacturing feedstock after proper disinfection and processing [2][3]. - Envetec's GENERATIONS® technology effectively converts regulated waste into recyclable polymer flakes through a low-energy chemical disinfection process, enabling the transformation of medical waste into new products [3][8]. Group 2: Industry Impact - The pilot project represents a significant step towards creating sustainable solutions for healthcare supply chains, allowing for the recovery and recycling of various plastic products [4][5]. - BD emphasizes the importance of single-use devices made from high-quality plastics in healthcare while acknowledging their environmental impact, indicating a commitment to circular economy solutions for healthcare consumables [5][6]. Group 3: Future Opportunities - Both BD and Envetec see potential for expanding the pilot project to reduce reliance on virgin plastics and maintain high-value polymers in circulation [4][6]. - Envetec is actively developing sustainable circular pathways for treated laboratory plastics, aiming to convert clean flakes into recycled pellets and new plastic products [6][8].

FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend rate is $4.20 per share. The company also announced it repurchased $250 million in BD stock to date in fiscal 2026. In addition, the board has authorized the compa ...

Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [4] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, reaching a record 25% [5][8] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [5] Business Line Data and Key Metrics Changes - The new BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [4] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [6] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [8] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [9] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [10] - The strategy aims to enhance customer experience, leverage AI and robotics for innovation, and ensure operational excellence for consistent cash flow growth [10][11] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful culmination of the BD 2025 strategy, marking the most prolific growth period in the company's history [6] - The company expressed confidence in its ability to maximize shareholder value through strategic capital allocation and a focus on high-growth markets [9] Other Important Information - The company announced its 54th consecutive year of dividend increases, reinforcing its commitment to a reliable dividend policy [5] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [9] Q&A Session Summary - No questions were received during the Q&A session, and the meeting concluded without any inquiries from shareholders [14]

Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [4] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, resulting in a record 25% adjusted operating margin [5][7] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [5] Business Line Data and Key Metrics Changes - New BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [4] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [6] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [7] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [8] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [9] - The capital allocation framework prioritizes share repurchases, reliable and increasing dividends, and focused tuck-in M&A in high-growth markets [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on the new growth strategy and emphasized the importance of operational excellence for reinvestment in commercial and innovation capabilities [9][10] - The company aims to maximize its platforms for faster long-term growth, building on the advancements made over the last five years [10] Other Important Information - The company announced its 54th consecutive year of dividend increases, reflecting the consistency and reliability of its dividend policy [5] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [8] Q&A Session Summary Question: Were there any questions from shareholders? - There were no questions received during the Q&A session [14]

Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [3] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, resulting in a record 25% adjusted operating margin [4] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [4] Business Line Data and Key Metrics Changes - New BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [3] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [5] - The company streamlined its portfolio by divesting non-strategic assets, including surgical instruments and diabetes businesses [5] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [6] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [7] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [8] - The capital allocation framework prioritizes share repurchases, reliable and increasing dividends, and focused tuck-in M&A in targeted high-growth markets [7] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful culmination of the BD 2025 strategy, achieving significant growth and building multiple high-growth platforms [5] - The company expressed confidence in its ability to raise standards and create more value for customers, patients, associates, and shareholders [9] Other Important Information - The company announced its 54th consecutive year of dividend increases, reflecting the consistency and reliability of its dividend policy [4] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [7] Q&A Session Summary - No questions were received during the Q&A session, and the meeting concluded without any inquiries [12]

Key Takeaways BDX launched BD Research Cloud 7.0 globally to expand its AI-driven flow cytometry platform.BDX added Horizon Panel Maker, using AI to speed and optimize research panel design.BDX said the platform improves lab workflows, collaboration, and software-driven revenue.Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the global commercial launch of BD Research Cloud 7.0, marking another step forward in its AI-driven life sciences strategy. The latest upgrade strengthe ...

Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Straumann Holding AG (SAUHY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate re ...